输血依赖型地中海贫血患者管理中的磁共振成像:单中心经验
研究评估106例输血依赖型地中海贫血患者心脏与肝脏T2*值与袪铁治疗的关系,按心脏T2*值分为高风险(<10 ms)、中风险(10-20 ms)和低风险(>20 ms)组。随访MRI显示肝铁浓度显著改善且与肝T2*值升高相关,DFX组肝铁浓度下降显著(p<0.01),血清铁蛋白与肝铁浓度及肝T2*值显著相关但与心脏T2*值无关。结论认为心血管与肝脏MRI是评估风险分组和袪铁治疗的有用随访工具。
要点
- 心脏T2*值<10 ms为高风险组,10-20 ms为中风险组,>20 ms为低风险组。
- 约80%患者按心脏T2*值、40%按肝脏T2*值初始处于低风险组。
- 随访MRI显示肝铁浓度改善与肝T2*值升高相关,DFX组肝铁浓度下降显著(p<0.01)。
核心结论
- 心血管与肝脏MRI是评估输血依赖型地中海贫血患者风险分组和袪铁治疗的有用随访工具,连续MRI检查能良好监测心脏和肝脏铁过载。
研究设计与样本
- 单中心研究,纳入在伊斯坦布尔医学院地中海贫血中心随访的106例输血依赖型地中海贫血患者,其中48例(45%)有超过一次连续MRI检查;按心脏T2*值分为高风险组(<10 ms)、中风险组(10-20 ms)和低风险组(>20 ms)。
诊断标准与关键数值
- 心脏T2*值<10 ms为高风险组,10-20 ms为中风险组,>20 ms为低风险组。
- 血清铁蛋白与肝铁浓度显著相关(rs=0.65,p<0.001),与肝T2*值显著相关(rs=-0.62,p<0.001),与心脏T2*值无显著相关(rs=-0.20,p=0.07)。
临床应用与阅片要点
- 随访MRI显示肝铁浓度改善与肝T2*值升高相关,DFX组肝铁浓度下降显著(p<0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Cardiac and hepatic magnetic resonance imaging evaluation during treatment can tailor physicians' chelation therapy titrations.
AIM: The aim of the study was to assess the relationship of cardiac and hepatic T2* values with chelation therapy in patients with transfusion-dependent thalassemia (TDT).
METHODS: A total of 106 patients with TDT who were followed up in Istanbul Medical Faculty Thalassemia Center were evaluated for the study. Forty-eight (45%) patients with TDT had more than one consecutive MRI examination. The patients were divided into three subgroups according to the cardiac T2* values as the high-risk group (T2* MRI < 10 ms), medium-risk group (T2* MRI 10-20 ms), and the low-risk group (T2* MRI > 20 ms).
RESULTS: The majority of patients used DFX (deferasirox) (79%) and deferiprone (DFP) (17%). Approximately 80% of patients according to cardiac T2* value and 40% of patients according to hepatic T2* value were initially in the low-risk group. Patients with follow-up MRI examinations exhibited significant improvement in liver iron concentration, which correlated with an increase in hepatic T2* values. The decrease of liver iron concentration was prominent in the DFX group (p < 0.01). The serum ferritin level was significantly correlated with liver iron concentrations (rs = 0.65, p < 0.001), hepatic T2* value (rs = - 0.62, p < 0.001), but not with cardiac T2* value (rs = - 0.20, p = 0.07).
CONCLUSION: Cardiovascular and hepatic MRI is a useful follow-up tool during the assessment of risk groups and chelation therapy of patients with TDT. Consecutive MRI tests showed good monitoring of cardiac and liver iron overload.
引用
- Karakas Z, Yilmaz Y, Bayramoglu Z, et al. Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience. Radiol Med. 2018. PMID: 29663188. doi:10.1007/s11547-018-0889-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。